Status:
WITHDRAWN
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Metastatic Colon Cancer
Eligibility:
All Genders
19+ years
Phase:
PHASE1
PHASE2
Brief Summary
This clinical study will investigate the utility of PET imaging with \[89Zr\]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If pr...
Eligibility Criteria
Inclusion
- Be at least 19 years of age.
- Diagnosis of colon cancer
- Scheduled to undergo surgical resection
Exclusion
- Inability to provide informed consent
- Pregnancy
- Inability to lie still for the imaging study
- Weight over 350 lbs., due to the scanner bore size
- Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)
- Inability to receive Omnipaque (iohexol) iodinated contrast
- Inability to receive glucagon
- Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent
- Allergy to contrast imaging agents
- Finding or suspicion of distant metastases on CT
Key Trial Info
Start Date :
March 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03764137
Start Date
March 14 2019
End Date
January 1 2026
Last Update
January 31 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.